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granules containing histamine, cytokines, chemokines, and proteases, including mast cell-speciﬁc chymase
and tryptase. Likemacrophages and T lymphocytes, mast cells are inﬂammatory cells, and they participate in
the pathogenesis of inﬂammatory diseases such as cardiovascular complications and metabolic disorders.
Recent observations suggested that mast cells are involved in insulin resistance and type 2 diabetes. Data from
animal models proved the direct participation of mast cells in diet-induced obesity and diabetes. Although the
mechanisms by which mast cells participate in these metabolic diseases are not fully understood, established
mast cell pathobiology in cardiovascular diseases and effective mast cell inhibitor medications used in pre-
formed obesity and diabetes in experimental models offer hope to patients with these common chronic
inﬂammatory diseases. This article is part of a Special Issue entitled: Mast cells in inﬂammation.cells in inﬂammation.
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Friedrich von Recklinghausen ﬁrst observed mast cells as granular
cells in frog mesenteries in 1863 [1]. About 12 years later, anatomist
Wilhelm Waldeyer detected mast cells in a tissue spread of rat dura
matter and named these cells “embryonal” or “plasma” cells [2]. In
1877, Waldeyer's medical student Paul Ehrlich stained mast cells with
aniline-positive dyes in connective tissues and named them Mastzel-
len, meaning “well-fed cells” because they had high numbers of
cytoplasmic granules [3]. Initially, mast cells were believed to be an
important component of connective tissues and to be differentiated
from ﬁbroblasts. Their biological functions were undeﬁned, as most
studies had been limited to histological descriptions. In the 1980s,
however, a growing body of evidence suggested that mast cells were
actually the progeny of hematopoietic stem cells (HSC) [4,5]. Unlike
other HSC offspring, such as neutrophils and erythrocytes—which
circulate in the blood as mature forms—mast cells do not ordinarily
circulate in mature forms. Instead, they migrate into mucosal or
connective tissues, where they undergo terminal differentiation and
maturation locally [6–9]. Mast cells are usually situated in the
interface of host–environment (i.e., skin and mucosa), enabling
them to respond rapidly to environmental stimuli.
A striking morphologic feature of mast cells is their abundance of
electron-dense secretory granules containing a wide variety ofmediators, such as histamine, which may increase vascular perme-
ability and alter vascular tone. Mature mast cells release these
granular mediators by explosive extrusion of mediator-containing
granules, which characterizes anaphylactic degranulation [10], or by
release of granular contents while retaining the granular membrane
within the cytoplasma, a process called piecemeal degranulation [11].
Mast cell mediators include cytokines such as interleukin 6 (IL6),
tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ), as well as
chemokines (e.g., IL8), proteases (cysteinyl cathepsins and matrix
metalloproteinases [MMPs]), and cell type-speciﬁc chymases and
tryptases [6,12–15]. Mast cells also can elaborate numerous lipid
mediators, including prostanoids and leukotrienes. Because they can
release these biologically active mediators in response to challenges
with IgE and speciﬁc antigens, mast cells are traditionally considered
critical effector cells in IgE-associated immediate hypersensitivity and
in allergic responses such as asthma [6,16,17]. But this conventional
concept is currently being modiﬁed, as recent progress has greatly
broadened mast cell functions in immune responses, ranging from
innate defense toward various pathogens [18] to multifaceted
regulators of adaptive immune responses [19,20]. Thus, mast cells
are gaining increased attention worldwide and not just limited to
asthma or allergic responses.
The recent ﬁndings related to the functions of mast cells ascribe to
the discovery of a mast cell-deﬁcient mouse model (KitW/Wv),
developed by Kitamura et al. [21]. These mice have a mutation in
the white spotting W locus that encodes c-kit, the receptor for stem
cell factor, which is an important cytokine for efﬁcient mast cell
development. The KitW defect is a point mutation that causes exon
skipping and produces a truncated receptor; KitW/W mice are not
viable because of the lack of the c-kit receptor. The KitW-v defect is a
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KitW-v/W-v mice have diminished Kit activity and a modest reduction
in mast cell numbers. KitW/W-v compound heterozygous mice—
combining the severe KitW mutation with the milder KitW-v muta-
tion—have markedly reduced Kit receptor activity and are severely
mast cell-deﬁcient (~1% of normal), but they are sterile and in amixed
genetic background. These phenotypes have limited the use of these
mice in mast cell biology in vivo studies. Another mast cell-deﬁcient
mouse model, KitW-sh/W-sh, was identiﬁed a few years after KitW/W-v
[22]. The KitW-shmutation is an inversion of a segment of chromosome
5 in the regulatory element of the Kit gene [23,24], which reduces Kit
gene expression. Unlike KitW/W-v mice, KitW-sh/W-shmice are fertile and
in a congenic C57BL/6 background—features that greatly beneﬁt
studies of mast cells and mast cell mediators in experimental disease
models. Both KitW/W-v and KitW-sh/W-sh mast cell-deﬁcient mice can be
corrected by adoptive transfer of in vitro cultured mast cells (Fig. 1).
Intravenous transfer of 1×107 of bone marrow-derived mast cells
(BMMCs) into recipient KitW-sh/W-sh mice leads to mast cell correction
in most organs, including the lungs, liver, spleen, lymph nodes, and
stomach [25]. But the efﬁciency of mast cell correction depends on
tissue type. By staining mast cells with connective tissue chymase
mMCP-4 (mouse mast cell protease-4) polyclonal antibody, we
detected comparable numbers of mast cells in atherosclerotic lesions
from low-density lipoprotein receptor-deﬁcient (Ldlr−/−) mice and
mast cell-deﬁcient (Ldlr−/−KitW-sh/W-sh) mice receiving 1×107 ofFig. 1. Strategies for mast cell reconstitution inmast cell-deﬁcient mice. Gene of interest
knockout mouse bone marrow-derived mast cells (BMMC) were cultured in IL3 and
stem cell factor and injected into tail veins of mast cell-deﬁcient KitW-sh/W-sh mice to
create mouse stains lacking the gene of interest only in mast cells. As a control, BMMC
cultured fromwild-type mice were injected into KitW-sh/W-shmice to generate wild-type
mast cell-reconstituted mice in the same mouse background. This experimental
procedure makes it possible to examine the molecular functions of individual mast cell
gene(s) in human disease models.donor mast cells. Complete correction of mast cells in Ldlr−/−
KitW-sh/W-sh mouse aortas restored the impaired atherosclerosis
phenotypes fully to those of Ldlr−/− mice [26]. The same numbers of
donor cells, however, corrected about 50%of KIT+mast cells in adipose
tissues from KitW-sh/W-sh mice, which led to 50% recovery of reduced
body weight in these mice [27]. This “mast cell knock-in” technique
hasmade it possible to study speciﬁc products ofmast cells in different
experimental disease models [25,28]. Comparison of the phenotypes
of KitW/W-v or KitW-sh/W-sh mice and mast cell-reconstituted KitW/W-v or
KitW-sh/W-shmice has revealed many in vivo functions of mast cells and
mast cell mediators in various human disease models [26–33].
Using mast cell-deﬁcient mouse models, several groups (including
our own) have revealed the roles of mast cells in cardiovascular
diseases over the last few years. Degranulated mast cells were found
in the interstitial myocardium in human hearts from normotensive
patients [30]. Several studies showed that mast cells accumulate in
human atherosclerotic plaques [34]. Recently, we reported that,
compared to low-density lipoprotein receptor-deﬁcient (Ldlr−/−)
mice, mast cell-deﬁcient Ldlr−/−KitW-sh/W-shmice in the same C57BL/6
background displayed signiﬁcantly impaired atherogenesis, de-
creased lesion size, lipid deposition, T cell and macrophage numbers,
cell proliferation, and apoptosis [26]. Greater mast cell numbers were
found during heart failure; therefore, mast cells may be involved in
the pathophysiology of heart failure. Hara et al. [35] used mast cell-
deﬁcient (WBB6F1/J background KitW/W-v) mice and their littermate
wild-type control mice to demonstrate that KitW/W-v mice showed
reduced cardiac hypertrophy and perivascular ﬁbrosis after aortic
constriction. Abdominal aortic aneurysm (AAA), a common aortic
disease in the elderly, is characterized by extensive tissue remodeling,
neovascularization, inﬂammatory cell inﬁltration, and vascular cell
apoptosis. A key feature of human AAA is leukocyte recruitment. Mast
cells—along with neutrophils, macrophages, and lymphocytes—
recently were identiﬁed in human aortic aneurysmal lesions [36,37].
Our group demonstrated that mast cell-deﬁcient KitW-sh/W-sh mice
failed to develop AAA. Adoptive transfer of BMMC fromwild-type and
Tnf−/− mice fully restored AAA formation in KitW-sh/W-sh mice, but
those from IL6-deﬁcient or INF-γ-deﬁcient mice did not—suggesting
that mast cell-derived IL6 and IFN-γ, but not TNF-α , are the prime
mediators from mast cells that contribute to AAA development [38].
Abdominal obesity, insulin resistance, hypertension, and dyslipid-
emia now are considered common risk factors for human cardiovas-
cular diseases. More than 50 years ago, Jean Vague ﬁrst described this
clustering of cardiovascular risk factors as metabolic syndromes [39].
In 1988, Reaven [40] re-introduced the concept of the clustering of
cardiovascular risk factors and proposed the name of Syndrome X,
suggesting that insulin resistance is the dominant underlying risk
factor. Several other names have been used to describe this syndrome,
including “the insulin-resistance syndrome” and “the cardiovascular
metabolic syndrome.” In 1998, the World Health Organization
proposed to use the name “metabolic syndrome” and suggested
parameters and criteria for its diagnosis. According to the proposal,
a person with impaired glucose tolerance (IGT) or type 2 diabetes
and/or insulin resistance, together with two or more of the other
components listed below, has the metabolic syndrome (Fig. 2)
[41,42]:
• Abdominal obesity, deﬁned as body mass index (BMI) ≥30 kg/m2,
and/or waist-to-hip ratio (WHR) N0.90 inmen and N0.85 inwomen;
• Increased arterial pressures (N160/90 mm Hg);
• Increased plasma triglycerides (N1.7 mmol/L) and/or low levels of
HDL cholesterol (b0.9 mmol/L in men, b1.0 mmol/L in women);
• Microalbuminuria (overnight urinary albumin excretion rate
≥20 μg/min).
In this short review, we will focus on the involvement of mast cells
in metabolic syndrome.
Fig. 2. Scheme of metabolic syndrome. Patients with impaired glucose tolerance (IGT)
and/or insulin resistance with two or more symptoms of hypertension, abdominal
obesity, microalbuminuria, and high triglyceride and/or lowHDL are considered to have
metabolic syndrome.
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The recent worldwide obesity pandemic has gained much
attention. Approximately one-third of U.S. adults are categorized as
overweight or obese. Inﬂammation is now considered to have a
pivotal role in the development of obesity. Obese adipose tissue shows
the hallmarks of chronic inﬂammation, with massive leukocyte
recruitment. Recent studies have described the accumulation of
macrophages in white adipose tissue (WAT) [43,44]. Xu and
colleagues compared gene expression in obese mice and in lean
controls. Many macrophage-speciﬁc genes—such as MAC-1, F4/80,
and CD68—are increased in WAT from obese mice; histological
analysis also shows a signiﬁcant increase in macrophages. Macro-
phage inﬁltration from the circulation likely explains this increase.
The augmentation of chemotaxin genes, such as monocyte chemoat-
tractant protein-1 (MCP-1), a chemoattractant speciﬁc for monocytes
and macrophages, also supports this conclusion. Weisberg et al.
proﬁled gene expression in WAT from mice with varying degrees of
obesity and found that macrophage accumulation in adipose tissue is
directly proportional to adiposity. Both body mass and adipocyte size
were strong predictors of the percentage of F4/80 macrophages in the
perigonadal, perirenal, mesenteric, and subcutaneous adipose tissue
depots.
Recent studies have found that T cells also accumulate inWAT.Wu
et al. [45] documented higher numbers of T cells in WAT of diet-Fig. 3. CD8+ T cells and mast cells in human and mouse WAT. WAT from obese humans and d
monoclonal antibody (1:75, Abcam, Cambridge, MA) and human tryptase monoclonal antibo
cells and mast cells. Mouse CD8 monoclonal antibody (1:300, Abcam) and mouse CD117 mo
cells and mast cells. Normal mouse IgG and rat IgG were used for immunohistochemical s
indicate immunopositive cells. V=microvessel. Scale bar: 100 μm.induced obese male mice than in WAT of lean mice. Both mRNA and
protein levels of RANTES, and its receptor CCR5, were increased in
WAT of obese mice, suggesting that RANTES/CCR5 may be important
in leukocyte accumulation. Rausch et al. [46] reported that CD8+ T
cells were present in large numbers within the adipose tissues of both
diet-induced obese mice and genetically generated ob/ob obese mice
(Fig. 3). These T cell subsets also appear in humanWAT (Fig. 3). T cells
and macrophages were intermittently found surrounding individual
adipocytes; T cells also formed large circular clusters around where
macrophages gathered. T lymphocytes cross talk with macrophages
and regulate the inﬂammatory cascade, but their functional role in
adipose inﬂammation remains unclear. Nishimura et al. [47] found
that CD8+ effector T cell inﬁltration precedes macrophage accumu-
lation and contributes to macrophage recruitment. Large numbers of
CD8+ effector T cells inﬁltrated obese epididymal adipose tissue in
mice fed a high-fat diet. Immunologic and genetic depletion of CD8+ T
cells lowered macrophage inﬁltration and adipose tissue inﬂamma-
tion, indicating that CD8+ T cells are required for maintenance of the
inﬂammatory response and that CD8+ T cells have major roles in
macrophage differentiation and migration. Adoptive transfer of CD8+
T cells to CD8-deﬁcient mice increased adipose inﬂammation, such as
enhanced macrophage inﬁltration and IL6 and TNF-α expression in
epididymal fat, and aggravated glucose intolerance and insulin
resistance. In contrast to the increased inﬁltration of CD8+ T cells,
however, CD4+ helper cells and T regulatory (Treg) cells were
strikingly reduced in obese mice [48]. Subsets of CD4+ T cells secrete
cytokines that can inhibit macrophage recruitment, including IL4 and
IL10 [49], whereas Treg cells suppress T cell, NK cell, NKT cell, B cell,
and dendritic cell activities, thereby controlling adaptive immune
responses [50]. Loss of Treg cells with increasing adiposity, therefore,
could allow an invasion of inﬂammatory macrophages. It remains
undeﬁnedwhether the inﬂux of macrophages or the efﬂux of Treg cells
proves upstream. Both processes must be downstream of an initiating
event, such as local hypoxia [51], increased death [52], and adipocyte
stress [53].
Mast cells, like macrophages or T cells, are inﬂammatory cells, but
the exact mechanisms of mast cells in the pathogenesis of obesity are
not fully understood. Staining human WAT sections with a mast cell
tryptase monoclonal antibody revealed high numbers of mast cells in
WAT from obese subjects (Fig. 3) compared with that of lean subjects,iet-induced obese mice were ﬁxed for parafﬁn section preparation (5 μm). Human CD8
dy (1:1500, Chemicon International, Billerica, MA) were used to detect human CD8+ T
noclonal antibody (1:40, eBioscience, San Diego, CA) were used to detect mouse CD8+ T
taining as negative controls for human and mouse WAT sections, respectively. Arrows
17J. Zhang, G.-P. Shi / Biochimica et Biophysica Acta 1822 (2012) 14–20though WAT had fewer mast cells than macrophages [27]. Obese
subjects also had signiﬁcantly higher tryptase concentrations in their
serum than did lean individuals. These observations suggest a possible
association between mast cells and obesity [27]. Similarly, WAT from
obese mice fed a high-fat diet contain higher numbers of Mac-2+
macrophages [27] and CD117+ mast cells (Fig. 3) than do lean
controls. Direct participation of mast cells in obesity was established
using mast cell-deﬁcient KitW-sh/W-sh mice. KitW-sh/W-sh mice, fed a
Western diet for 12 weeks gained signiﬁcantly less body weight, had
improved glucose intolerance and had reduced adipose tissue
inﬂammation with reduced leptin and insulin levels in the circulation,
compared with congenic wild-type controls. Consistently, wild-type
mice receiving a daily intraperitoneal injection of the mast cell
stabilizer disodium cromoglycate (DSCG) also had attenuated body
weight gain. Adoptive transfer experiments of different cytokine-
deﬁcient mast cells into KitW-sh/W-sh mice (Fig. 1) demonstrated that
mast cells contributed to diet-induced obesity by producing the
inﬂammatory cytokines IL6 and IFN-γ. KitW-sh/W-sh mice receiving
BMMCs from IL6−/−mice and Ifng−/−mice, but not wild-type mice or
Tnf−/− mice, showed less body weight gain and improved glucose
tolerance. In addition to releasing cytokines, mast cells may contribute
to obesity by promoting angiogenesis. Mast cells are often localized
next to microvessels in WAT (Fig. 3). The numbers of microvessels
correlated with the increase in mast cell numbers during the
development of obesity. WAT and muscle tissues from wild-type
obese mice showed substantial immunostaining of CD31 (micro-
vessels) and KIT (mast cells), signiﬁcantly more than those fromwild-
type leanmice [27]. Although not tested, high numbers of mast cells in
WAT from obese mice may result from enhanced mast cell
proliferation, reduced mast cell apoptosis, or increased mast cell
recruitment—all of which may contribute to angiogenesis in WAT.
Indeed, we detected signiﬁcantly higher levels of chemokineMCP-1 in
WAT from obesemice than inWAT from leanmice [27]. Western diet-
fed KitW-sh/W-sh mice or those receiving DSCG had smaller CD31+
areas, similar to those from chow diet-fed lean mice. Reduced
angiogenesis in KitW-sh/W-sh mice or those receiving DSCG resulted in
high numbers of apoptotic cells in WAT and muscle tissues. Mast cells
contain cell type-speciﬁc chymases and tryptases. Although there is
no data to suggest that thesemast cell proteases participate directly in
obesity, the ﬁndings in our recent AAA study indicate that mast cell
chymase plays an important role in angiogenesis. While BMMC from
wild-type mice promoted microvessel sprouting in an aortic ring
assay, those from chymase-deﬁcient mice showed signiﬁcantly
reduced potency to microvessel sprouting [54]. Besides these cell
type-speciﬁc proteases, mast cells also contain high levels of the
cysteine proteases, cathepsin S, and cathepsin L [55]. Both cathepsins
are critical to angiogenesis during tumor growth [56], wound healing
[57], and AAA expansion (Shi, unpublished data). Indeed, WAT
protein extracted from obese wild-type mice contained higher levels
of cathepsins B, S, and L than that from KitW-sh/W-sh mice [27].
Inﬂammatory cells, such as macrophages, CD4+ and CD8+ T cells,
regulatory T cells, and mast cells, all localize in WAT in humans and in
mice. These observations leave many important questions to be
answered. First, we ask what triggers the ﬁrst inﬂammatory cell
inﬁltration to WAT and which cell type appears ﬁrst in WAT. Using
KitW-sh/W-sh mice and mast cell stabilizer DSCG, we indirectly proved
that mast cells inﬁltrate intoWAT beforemacrophages. Inactivation of
mast cells with DSCG did not affect mast cell recruitment to the WAT,
but it signiﬁcantly blocked macrophage accumulation in WAT [27].
We are interested in what cells trigger mast cell migration during
WAT growth. Second, macrophages and mast cells interact with
different T cells by many mechanisms, such as major histocompati-
bility (MHC) class II-mediated antigen presentation or direct release
of inﬂammatory cytokines, which have not been studied in WAT. It is
possible that macrophages and mast cells, although they are non-
professional antigen-presenting cells, participate in T cell activationusing the same mechanisms as those in lymphoid organs. Thus,
inﬂammation may play a detrimental role in obesity. Third, why
mastocytosis patients with excess amounts of mast cells are not
always obese, although many are diabetic (R.S. Fredericks, Endocrine
Associates, Reno, NV: personal communication), remains unex-
plained. Therefore, other mechanisms may also control body weight
gain in obese patients.
3. Mast cells in insulin resistance and type 2 diabetes
Diabetes mellitus is a metabolic syndrome characterized by
hyperglycemia and associated with microvascular and macrovascular
complications. Type 1 and type 2 are the most common types of
diabetes. Obesity is a major risk factor for insulin resistance and type 2
diabetes. Although how obesity promotes insulin resistance is unclear,
the inﬂammatory response is thought to be a potentially important
mechanism, which could alter adipose tissue function, thus leading to
systemic insulin resistance. The development of insulin resistance
associates with proinﬂammatory cytokines produced by inﬁltrating
leukocytes and resident adipocytes within the adipose tissue in obese
subjects [58]. As discussed earlier, WAT is a reservoir of different
leukocytes, including macrophages, T cells, and mast cells. These cells
are rich sources of proinﬂammatory cytokines. Hotamisligil et al. [59]
and Feinstein et al. [60] showed that proinﬂammatory TNF-αwas able
to mediate insulin resistance. TNF-α is overexpressed in WAT from
obese subjects. Lack of TNF-α ligand or the p55 TNF receptor improves
insulin sensitivity and glucose homeostasis, suggesting that this
inﬂammatory response is important in the regulation of insulin action
in obesity [14,61–63]. The widespread use of anti-TNF-α treatment in
patients with inﬂammatory diseases such as rheumatoid arthritis and
ankylosing spondylitis yielded signiﬁcant reduction of blood insulin
levels and insulin/glucose index, as well as decrease of the
homeostasis model assessment (HOMA) index and increase of the
quantitative insulin sensitivity check index (QUICKI) among patients
with high insulin resistance, supporting a role for TNF-α in systemic
insulin sensitivity in humans [58,64,65]. Other inﬂammatory media-
tors and cytokines are also overexpressed inWAT, including IL6, iNOS,
MCP-1, and IL1. Many of these inﬂammatory molecules cause insulin
resistance in adipocytes [66–68].
Our work discussed earlier [27] suggested that mast cells
contribute directly to insulin resistance and type 2 diabetes. Using
diet-induced experimental type 2 diabetes, we demonstrated that
mast cell-deﬁcient KitW-sh/W-sh mice had higher insulin sensitivity and
glucose tolerance than wild-type control mice on a Western diet.
Wild-type mice receiving DSCG treatment also showed increases in
these parameters, compared to control mice. Diabetic mice had high
serum insulin and glucose levels and high numbers of KIT-positive
mast cells in WAT. In contrast to many other studies, mast cell
stabilization not only prevented diet-induced obesity and diabetes in
mice but also had therapeutic beneﬁt. Cromolyn (DSCG) and Zaditor
(also called ketotifen), two common mast cell stabilizers used in
human allergic diseases, reversed pre-established obesity and
diabetes in mice. After consuming a high-fat diet for 3 months,
wild-type mice became obese and diabetic. But intraperitoneal
administration of DSCG or ketotifen reduced both body weight and
glucose intolerance in mice that were kept on the same high-fat diet.
After switching to a chow diet, obese and diabetic mice had normal
body weight and glucose tolerance after 2 months of treatment with
either DSCG or ketotifen—which was no different from mice that
consumed a chow diet at the same ages [27]. These observations offer
new hope for patients suffering from these metabolic disorders.
Patients with obesity or diabetes may beneﬁt from mast cell
stabilization.
Long-term uncontrolled diabetes has numerous complications,
such as neurophathy, retinopathy, nephropathy, cardiomyopathy,
vasculopathy, dermatopathy, and encephalopathy [69]. The role of
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elsewhere [69,70] and will be only brieﬂy covered here. Diabetic
nephropathy is one of the major microvascular complications of
diabetes, characterized by excessive amassing of extracellular matrix
with thickening of glomerular and tubular basement membranes and
increased mesangial matrix, which ultimately progress to glomerulo-
sclerosis and tubulo-interstitial ﬁbrosis [71]. Mast cells are found
infrequently in normal kidney tissue, but mast cell inﬁltration is a
prominent and early feature following renal injury [72]. Increased
mast cell density has been noted in the kidneys of diabetic patients
with nephropathy [73,74]. Mast cells participated in renal interstitial
ﬁbrosis and produced the non-ﬁbrillar short chain type VIII collagen,
suggesting that mast cells are associated with ﬁbrosis and extracel-
lular matrix accumulation in human diabetic nephropathy. But the
mechanism by which mast cells mediate diabetic nephropathy
remains unclear. Mast cell degranulation leads to the release of
various mediators, such as TGF-β, chymase, tryptase, cathepsin G,
rennin, and many others that may contribute to renal diseases. For
instance, TGF-β is a potent proﬁbrotic growth factor that is widely
implicated in the pathogenesis of progressive renal disease [75].
Tryptase, the major mast cell enzyme, promotes renal ﬁbroblast
proliferation and collagen synthesis [76]. Chymase, a family of serine
protease in mast cells, converts the biologically inactive form of TGF-β
into an active form [77]. More evidence is still needed to conﬁrm
direct involvement of these mast cell-derived mediators in diabetic
nephropathy.
4. Mast cells in hypertension
Hypertensive heart disease is the major cause of diastolic heart
failure and other related heart diseases. Excessive myocardial ﬁbrosis
impairs cardiac function in hypertensive heart disease. Myocardial
ﬁbrosis has been described in experimental hypertension in rats [78],
and it contains excessive protein deposition, mainly including type I
and type III collagens [79] that may result from increased synthesis or
decreased degradation of these matrix proteins. Inﬂammatory cell
recruitment closely associates with the development of left ventric-
ular ﬁbrosis induced by hypertension. Hinglais et al. [80] explored the
relationship between left ventricular ﬁbrosis and inﬂammatory cell
inﬁltration in spontaneously hypertensive rats (SHR). The area of
ﬁbrosis and interstitial cellular inﬁltrates were greater in SHR than in
Wistar controls. In 12-month-old rats, ﬁbroblasts colocalized with
inﬂammatory cells, and the density of ED-1+ macrophages and CD4+
lymphocytes were increased in the ﬁbrosis area. There were fewer
CD8+ cells than any other cell type (CD4+ cells, macrophages, and
MHC class II-positive cells) in renovascular hypertensive rats,
indicating that cytotoxic lymphocytes are not greatly involved in
this inﬂammatory process [81]. Kuwahara et al. [82,83] reported that,
after a pressure overload created by a suprarenal abdominal aorta
constriction, Wistar rats showed a rapid progression of marked
reactive myocardial ﬁbrosis. Using this model, they examined the role
of macrophages in myocardial remodeling and cardiac dysfunction
[83]. Pressure overload induced pericular macrophage accumulation,
with a peak at day 3 and decreasing to lower levels by day 28. MCP-1,
an important chemokine for macrophage migration, also increased
after day 1, peaking at day 3 and returning to insigniﬁcant levels by
day 28. Chronic treatment with an anti-MCP-1 monoclonal neutral-
izing antibody inhibited macrophage accumulation, suggesting that
inhibition of inﬂammation is a new strategy to prevent myocardial
ﬁbrosis in hypertensive heart disease. Kagitani et al. administered
N-(3′,4'-dimethyoxycinnamoyl) anthranilic acid (tranilast), an anti-
inﬂammatory drug, by inhibiting lipid and inﬂammatory mediator
release from inﬂammatory cells to deoxycorticosterone-acetate
(DOCA) hypertensive mice. Although systolic blood pressure was
similar in animals treated with tranilast or vehicle, monocyte/
macrophage inﬁltration was suppressed, and mRNA expression ofTGF-β1, type-1 plasminogen activator inhibitor, MCP-1, IL6, procol-
lagen I, and procollagen III was attenuated. Myocardial ﬁbrosis and
collagen accumulationwere also suppressed [84], suggesting that the
myocardial ﬁbrosis seen in DOCA/salt hypertensive rats associates
with inﬂammation.
Mast cell functions in hypertension are often overlooked because
of the striking features of macrophages and T cells in inﬂammation.
Olivetti et al. [85] reported a more than three-fold increase in the
numerical density of mast cell proﬁles in the myocardium related
with capillary proliferation after pulmonary artery constriction. The
interaction between mast cell number and capillary proliferation is
poorly understood [86]. One possible explanation is that mast cells
release heparin, which appears to be responsible for endothelial cell
migration [87] and the ingrowth of new capillary units. Shiota et al.
found that the density of cardiac mast cells is already signiﬁcantly
increased in SHRs immediately after birth. Moreover, the cardiac mast
cell density was signiﬁcantly higher in SHRs than in age-matched
non-hyperactive Wistar–Kyoto (WKY) control rats throughout their
life span. Mast cells produce TNF-α together with nuclear factor
kappa-B (NF-κB) and IL6. These transcription factors and cytokines
were induced signiﬁcantly in prehypertensive SHRs. In the late
hypertensive stage, the hearts of SHRs displayed increased areas of
myocardial ﬁbrosis, where activated mast cells are localized. The
expressions of TGF-β1 and basic ﬁbroblast growth factor (bFGF) were
signiﬁcantly increased in the aging and failing SHR hearts [88]. Mast
cells were major sources of TGF-β1 and bFGF, although other heart
cells also expressed these growth factors. Taken together, cardiac
mast cells participate in the induction of cardiac hypertrophy and
cardiac ﬁbrosis by synthesizing and secreting prohypertrophic
cytokines and proﬁbrotic growth factors. Panizo et al. [89] reported
that there is a positive correlation between cardiac mast cell density
and the volume of the collagen fraction in the hypertrophied left
ventricles of SHRs. Interestingly, Hara et al. [35] found that
perivascular collagen was normal in mast cell-deﬁcient KitW/Wv mice
after aortic banding. Recently, Levick et al. [90] identiﬁed a causal
relationship between cardiac mast cells and the regulation of ﬁbrosis
in the hypertensive heart. Eight-week-old male SHRs were treated for
12 weeks with the mast cell stabilizing compound nedocromil. Left
ventricular ﬁbrosis was prevented, independent of hypertrophy and
blood pressure. There are several potential mechanisms by which
mast cells mediate their proﬁbrotic actions. Mast cells produce a
variety of proteases, cytokines, growth factors, and other biologically
active mediators that may inﬂuence tissue remodeling. Notably,
tryptase was elevated in untreated SHRs but normalized after
nedocromil treatment. Tryptase is likely not the only mediator
responsible; cytokines IFN-γ and IL4 were increased in SHRs and
normalized by nedocromil, whereas IL6 and IL10 were decreased in
SHRs, with nedocromil treatment normalizing IL6 and increasing IL10.
In addition, nedocromil also prevented macrophage inﬁltration into
the ventricle, suggesting that intercellular signaling between the
inﬂammatory cells is important in mediating ﬁbrosis.
5. Mast cells in dyslipidemia
Atherosclerosis is characterized by the accumulation of low-
density lipoprotein (LDL)-driven cholesterol in the intima, the inner
layer of the arterial wall. Macrophages uptake LDL particles, leading to
the formation of foam cells. In addition to macrophages, mast cells are
present in the arterial intima and are in the close vicinity of foam cells
[91], suggesting that mast cells are involved in the transformation of
macrophages into foam cells. As discussed, upon stimulation,
activated mast cells extrude their granules into the extracellular
space. There, they lose their soluble components, such as histamine,
but their two neutral proteases, chymase and carboxypeptidase A,
remain tightly bound to the heparin proteoglycan, thereby forming
insoluble granule “remnant.” LDL binds to the heparin proteoglycan of
19J. Zhang, G.-P. Shi / Biochimica et Biophysica Acta 1822 (2012) 14–20these mast cell granule remnants and forms insoluble complexes.
These insoluble complexes are then phagocytosed by macrophages,
forming macrophage foam cells [92,93]. When mast cells were
activated by intraperitoneal administration of C48/80, a laboratory-
use mast cell activator, LDL uptake by macrophages rose by 7–24-fold
[94]. Like 48/80-triggered mast cell stimulation, IgE-dependent
stimulation of sensitized mast cells also leads to increased uptake of
LDL by cocultured macrophages and thereby foam cell formation
[95,96]. In contrast, the mast cell stabilizer cromolyn effectively
blocked mast cell-dependent LDL uptake by macrophages [95]. Along
with LDL particles, high-density lipoprotein (HDL) particles cons-
tantly pass from the bloodstream into the arterial intima [91]. HDL3
particles promote the transfer of cholesterol from the arterial intima
back to the bloodstream. When mast cells are stimulated to
degranulate, however, the chymase-containing granule remnants
derived from degranulating rat serosal mast cells rapidly degrade the
HDL3 components apolipoprotein E (ApoE), ApoA-I, and ApoA-IV in
plasma, peritoneal ﬂuid, and possibly in atherosclerotic lesions. Thus,
the net efﬂux of cholesterol promoted by HDL frommacrophage foam
cells is impaired [91,97]. Recently, Heikkila et al. [98] reported
signiﬁcant differences in serum lipid and lipoprotein proﬁles between
mast cell-deﬁcient (KitW-sh/w-sh) mice and wild-type mice. KitW-sh/w-sh
mice on an Ldlr−/− background have lower levels of serum total
cholesterol, triglycerides, and phospholipids, thus displaying a less
atherogenic lipoprotein proﬁle. The reduction in triglycerides and
phospholipids inmast cell-deﬁcient micemay call for future studies in
this important ﬁeld of lipoprotein metabolism.Acknowledgments
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